Calf Blood Compound (CFC) and Homeopathic Drug Induce Differentiation of Primary Human Skeletal Muscle Cells

Abstract

The use of injections to treat structural muscle injuries is controversially discussed. In our controlled in vitro study, we investigated the biological impact of Actovegin and Traumeel alone and in combination on primary human skeletal muscle cells. Cells were characterized by immunofluorescence staining for myogenic factor 5 (Myf5) and MyoD, and cultured with or without Actovegin and / or Traumeel. The effects of these agents were assayed by cell viability and gene expression of the specific markers MyoD, Myf5, neural adhesion molecule (NCAM), and CD31. Myotube formation was determined by myosin staining. Neither Actovegin nor Traumeel showed toxic effects or influenced cell viability significantly. High volumes of Actovegin down-regulated gene expression of NCAM after 3 days but had no effect on MyoD, Myf5, and CD31 gene expression. High volumes of Traumeel inhibited MyoD gene expression after 3 days, whereas after 7 days MyoD expression was significantly up-regulated. The combination of both agents did not significantly influence cell viability or gene expression. This is the first study demonstrating that Actovegin and Traumeel potentially modulate human skeletal muscle cells. The relevance of these in vitro findings has to be highlighted in further in vivo studies.

Key words

muscle injury - Calf Blood Copmpound^® - Homeopathic Drug^®

• References

• 1 Ekstrand J, Hagglund M, Walden M. Epidemiology of muscle injuries in professional football (soccer). Am J Sports Med 2011; 39: 1226-1232
• 2 Orchard JW, Best TM, Mueller-Wohlfahrt HW, Hunter G, Hamilton BH, Webborn N, Jaques R, Kenneally D, Budgett R, Phillips N, Becker C, Glasgow P. The early management of muscle strains in the elite athlete: Best practice in a world with a limited evidence basis. Br J Sports Med 2008; 42: 158-159
• 3 Wright-Carpenter T, Klein P, Schaferhoff P, Appell HJ, Mir LM, Wehling P. Treatment of muscle injuries by local administration of autologous conditioned serum: A pilot study on sportsmen with muscle strains. Int J Sports Med 2004; 25: 588-593
• 4 Hotfiel T, Seil R, Bily W, Bloch W, Gokeler A, Krifter RM, Mayer F, Ueblacker P, Weisskopf L, Engelhardt M. Nonoperative treatment of muscle injuries - recommendations from the GOTS expert meeting. J Exp Orthop 2018; 5: 24
• 5 MS AH Mohamed Ali MR Yusof A George J Lee LP Platelet-rich plasma injections for the treatment of hamstring injuries: A randomized controlled trial. Am J Sports Med 2014; 42: 2410-2418
• 6 Reurink G, Goudswaard GJ, Moen MH, Weir A, Verhaar JA, Tol JL. Myotoxicity of injections for acute muscle injuries: A systematic review. Sports Med 2014; 44: 943-956
• 7 Reurink G, Goudswaard GJ, Tol JL, Verhaar JA, Weir A, Moen MH. Therapeutic interventions for acute hamstring injuries: A systematic review. Br J Sports Med 2012; 46: 103-109
• 8 Rossi LA, Molina Romoli AR, Bertona Altieri BA, Burgos Flor JA, Scordo WE, Elizondo CM. Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial. Knee Surg Sports Traumatol Arthrosc 2017; 25: 3319-3325
• 9 Ueblacker P, English B, Mueller-Wohlfahrt HW. Nonoperative treatment and return to play after complete proximal adductor avulsion in high-performance athletes. Knee Surg Sports Traumatol Arthrosc 2016; 24: 3927-3933
• 10 Ueblacker P, Haensel L, Mueller-Wohlfahrt HW. Treatment of muscle injuries in football. J Sports Sci 2016; 34: 2329-2337
• 11 Hammond JW, Hinton RY, Curl LA, Muriel JM, Lovering RM. Use of autologous platelet-rich plasma to treat muscle strain injuries. Am J Sports Med 2009; 37: 1135-1142
• 12 Wright-Carpenter T, Opolon P, Appell HJ, Meijer H, Wehling P, Mir LM. Treatment of muscle injuries by local administration of autologous conditioned serum: Animal experiments using a muscle contusion model. Int J Sports Med 2004; 25: 582-587
• 13 Andia I, Abate M. Platelet-rich plasma in the treatment of skeletal muscle injuries. Expert Opin Biol Ther 2015; 15: 987-999
• 14 Reurink G, Goudswaard GJ, Moen MH, Weir A, Verhaar JA, Bierma-Zeinstra SM, Maas M, Tol JL. Dutch HITsI. Rationale, secondary outcome scores and 1-year follow-up of a randomised trial of platelet-rich plasma injections in acute hamstring muscle injury: The Dutch Hamstring Injection Therapy study. Br J Sports Med 2015; 49: 1206-1212
• 15 Reichl FX, Holdt LM, Teupser D, Schutze G, Metcalfe AJ, Hickel R, Hogg C, Bloch W. Comprehensive analytics of Actovegin(R) and its effect on muscle cells. Int J Sports Med 2017; 38: 809-818
• 16 Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. Actovegin(R): A biological drug for more than 5 decades. Wien Med Wochenschr 2011; 161: 80-88
• 17 Vanden Bossche L, Vanderstraeten G. A multi-center, double-blind, randomized, placebo-controlled trial protocol to assess Traumeel injection vs. dexamethasone injection in rotator cuff syndrome: The TRAumeel in ROtator cuff syndrome (TRARO) study protocol. BMC Musculoskelet Disord 2015; 16: 8
• 18 Porozov S, Cahalon L, Weiser M, Branski D, Lider O, Oberbaum M. Inhibition of IL-1beta and TNF-alpha secretion from resting and activated human immunocytes by the homeopathic medication Traumeel S. Clin Dev Immunol 2004; 11: 143-149
• 19 Stewart JD, Masi TL, Cumming AE, Molnar GM, Wentworth BM, Sampath K, McPherson JM, Yaeger PC. Characterization of proliferating human skeletal muscle-derived cells in vitro: Differential modulation of myoblast markers by TGF-beta2. J Cell Physiol 2003; 196: 70-78
• 20 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408
• 21 Harriss DJ, Macsween A, Atkinson G. Standards for ethics in sport and exercise science research: 2018 update. Int J Sports Med 2017; 38: 1126-1131
• 22 Pfister A, Koller W. [Treatment of fresh muscle injury]. Sportverletz Sportschaden 1990; 4: 41-44
• 23 Astashkin EI, Glezer MG, Vinokurov MG, Egorova ND, Orekhova NS, Novikova AN, Grachev SV, Yurinskaya MM, Sobolev KE. Actovegin reduces the ROS level in blood samples of heart failure patients and diminishes necrosis of SK-N-SH human neuroblastoma cells. Dokl Biol Sci 2013; 448: 57-60
• 24 Ciciliot S, Schiaffino S. Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications. Curr Pharm Des 2010; 16: 906-914
• 25 Miltenburger HG, Baschong W, Horner V, Marx G. Cooperative effects in vitro on fibroblast and keratinocyte functions related to wound healing by transforming growth factor-beta and a low molecular weight fraction from hemolyzed blood. Arzneimittelforschung 1994; 44: 872-876
• 26 Brock J, Golding D, Smith PM, Nokes L, Kwan A, Lee PYF. Update on the role of Actovegin in musculoskeletal medicine: A review of the past 10 years. Clin J Sport Med 2018; DOI: 10.1097/JSM.0000000000000566.
• 27 Muders K, Pilat C, Deuster V, Frech T, Kruger K, Pons-Kuhnemann J, Mooren FC. Effects of Traumeel (Tr14) on exercise-induced muscle damage response in healthy subjects: A double-blind RCT. Mediators Inflamm 2016; 2016: 1693918
• 28 Muders K, Pilat C, Deuster V, Frech T, Kruger K, Pons-Kuhnemann J, Mooren FC. Effects of Traumeel (Tr14) on recovery and inflammatory immune response after repeated bouts of exercise: A double-blind RCT. Eur J Appl Physiol 2017; 117: 591-605
• 29 Schneider C. Traumeel – an emerging option to nonsteroidal anti-inflammatory drugs in the management of acute musculoskeletal injuries. Int J Gen Med 2011; 4: 225-234